Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087991 · ClinicalTrials.gov registry record
Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
A clinical trial, sponsored by Jerry Cochran.
- Completed
- Registry status
- 65
- Enrollment target
NCT06087991: Completed study, sponsored by Jerry Cochran.
NCT06087991 is a clinical trial that has completed, run by Jerry Cochran. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06087991 has completed, sponsored by Jerry Cochran.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.
Primary Outcome
Will be the aggregate number of individuals who received ED-initiated buprenorphine.
Interventions
- BEHAVIORAL Implementation of the BINDeR-Tx service model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2024-10-01 |
What the finished NCT06087991 record still lists
NCT06087991 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Implementation of the BINDeR-Tx service model is the first listed.
NCT06087991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06087991 about?
NCT06087991 is a clinical study titled "Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment". This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refer...
What is the current status of trial NCT06087991?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2023-04-01. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT06087991?
The interventions under investigation include: Implementation of the BINDeR-Tx service model (BEHAVIORAL).
Who is sponsoring clinical trial NCT06087991?
This trial is sponsored by Jerry Cochran, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI